PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
111.14%
Revenue growth 1.25-1.5x ACB.TO's 100.00%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
91.08%
Gross profit growth of 91.08% while ACB.TO is zero. Bruce Berkowitz would see if minimal improvements could expand further.
10.33%
Positive EBIT growth while ACB.TO is negative. John Neff might see a substantial edge in operational management.
10.33%
Operating income growth under 50% of ACB.TO's 43.62%. Michael Burry would be concerned about deeper cost or sales issues.
10.46%
Positive net income growth while ACB.TO is negative. John Neff might see a big relative performance advantage.
10.98%
EPS growth under 50% of ACB.TO's 29.69%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
10.98%
Diluted EPS growth under 50% of ACB.TO's 29.69%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-1.98%
Share reduction while ACB.TO is at 10.16%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
0.00%
Diluted share reduction more than 1.5x ACB.TO's 10.16%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
48.20%
OCF growth at 50-75% of ACB.TO's 68.44%. Martin Whitman would question if the firm lags in monetizing sales effectively.
11.57%
FCF growth under 50% of ACB.TO's 79.07%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-109.58%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-109.58%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-888.70%
Negative 3Y OCF/share CAGR while ACB.TO stands at 43.85%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-9.81%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-9.81%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-28.19%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
19.21%
Positive growth while ACB.TO is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
19.21%
Positive 5Y equity/share CAGR while ACB.TO is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
135.88%
Positive short-term equity growth while ACB.TO is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
24.20%
Our AR growth while ACB.TO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-2.65%
Inventory is declining while ACB.TO stands at 1137.19%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-1.88%
Negative asset growth while ACB.TO invests at 2.74%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-0.13%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
-37.31%
Our R&D shrinks while ACB.TO invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
53.56%
SG&A declining or stable vs. ACB.TO's 232.20%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.